Perceptive Advisors LLC Takes Position in Twist Bioscience Corporation $TWST

Perceptive Advisors LLC acquired a new stake in shares of Twist Bioscience Corporation (NASDAQ:TWST) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 150,000 shares of the company’s stock, valued at approximately $7,128,000.

Other large investors also recently bought and sold shares of the company. SG Americas Securities LLC increased its holdings in shares of Twist Bioscience by 350.3% in the 4th quarter. SG Americas Securities LLC now owns 76,484 shares of the company’s stock valued at $2,426,000 after acquiring an additional 59,500 shares during the period. UBS Group AG raised its position in shares of Twist Bioscience by 28.6% in the 4th quarter. UBS Group AG now owns 662,317 shares of the company’s stock worth $21,009,000 after acquiring an additional 147,389 shares in the last quarter. Tudor Investment Corp ET AL purchased a new stake in shares of Twist Bioscience during the 3rd quarter worth $717,000. Allspring Global Investments Holdings LLC purchased a new stake in shares of Twist Bioscience during the 1st quarter worth $22,563,000. Finally, Pictet Asset Management Holding SA boosted its position in Twist Bioscience by 108.5% during the fourth quarter. Pictet Asset Management Holding SA now owns 222,647 shares of the company’s stock valued at $7,302,000 after purchasing an additional 115,880 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. UBS Group set a $89.00 target price on Twist Bioscience in a research note on Monday, June 15th. Canaccord Genuity Group increased their price target on shares of Twist Bioscience from $90.00 to $120.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a report on Wednesday, June 24th. Evercore cut shares of Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price target on the stock. in a report on Monday, July 6th. Finally, Robert W. Baird lifted their price objective on shares of Twist Bioscience from $50.00 to $65.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 5th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Twist Bioscience presently has an average rating of “Moderate Buy” and an average target price of $90.30.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, insider Dennis Cho sold 14,205 shares of the company’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $89.75, for a total value of $1,274,898.75. Following the sale, the insider directly owned 105,141 shares of the company’s stock, valued at approximately $9,436,404.75. This represents a 11.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Adam Laponis sold 2,399 shares of the stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $94.33, for a total value of $226,297.67. Following the sale, the chief financial officer directly owned 110,276 shares in the company, valued at $10,402,335.08. This represents a 2.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 50,211 shares of company stock valued at $4,199,331. 3.08% of the stock is owned by corporate insiders.

Twist Bioscience Price Performance

Shares of NASDAQ TWST opened at $91.55 on Friday. Twist Bioscience Corporation has a 52 week low of $23.30 and a 52 week high of $105.47. The business’s 50 day moving average price is $84.99 and its 200 day moving average price is $61.96. The company has a quick ratio of 2.42, a current ratio of 2.70 and a debt-to-equity ratio of 0.03. The firm has a market cap of $5.70 billion, a P/E ratio of -68.83 and a beta of 2.11.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, May 4th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.22). Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.The business had revenue of $110.72 million for the quarter, compared to analysts’ expectations of $107.64 million. During the same period in the prior year, the business posted ($0.66) earnings per share. The business’s quarterly revenue was up 19.3% compared to the same quarter last year. On average, sell-side analysts expect that Twist Bioscience Corporation will post -2.02 earnings per share for the current year.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.